© 2021 MJH Life Sciences and Center for Biosimilars®. All rights reserved.
© 2021 MJH Life Sciences™ and Center for Biosimilars®. All rights reserved.
November 24 2020
San Antonio Breast Cancer Symposium
GP2 peptide/G-CSF in HER2-equivocal and -positive breast cancer has shown promise.
November 23 2020
ESMO ASIA Virtual Congress 2020
Bevacizuamb biosimilar in combination with sintilimab delivered significantly improved overall survival vs sorafenib.
November 20 2020
ACR Convergence 2020
The FDA naming convention and its utility are not well understood, and “poor” biosimilar knowledge may be partly to blame, investigators report.
November 19 2020
Prior to the turmoil of the pandemic, the FDA and CMS were at work on shoring up the biosimilars market, and this work continues on various fronts, a regulatory/policy expert explains.
November 17 2020
Despite a rocky power transition at the federal level, the compass heading for biosimilars is unchanged, said policy expert Molly Burich.
November 16 2020
Investigators said their study is valuable because biosimilar switching is likely to increase for economic reasons.
Investigators looked at adherence in patients who switched from reference infliximab during treatment for rheumatologic and gastrointestinal treatment.
November 14 2020
Festival of Biologics Basel
In Europe, the pandemic has revealed problems within health care systems and the need to increase access to biosimilars and reform health care policies.
November 11 2020
HHS Secretary Alex M. Azar said efforts and policies to counter a sharply upward drug price trend have been successful, in a talk with the Association for Accessible Medicine.
November 10 2020
Sarah Yim, MD, director of the Office of Therapeutic Biologics and Biosimilars (OTBB), highlighted the ways the FDA is working to remove blocks and wedges hindering biosimilars.